Business Context and Reporting Period
Passage Bio, Inc. filed this Form 8-K on December 17, 2021 under Items 7.01 and 8.01. The filing reports clinical development updates for PBGM01, an investigational gene therapy for early and late infantile GM1 gangliosidosis, and other pipeline-program updates. The filing is not a periodic financial report.
Key Financial Metrics and Liquidity
The filing does not provide revenue, net income, cash flow, margins, debt, cash balances, liquidity measures, or other financial metrics.
Material Changes and Clinical Updates
- The Independent Data Monitoring Committee recommended proceeding with two additional planned cohorts in the global Phase 1/2 Imagine-1 study.
- Recruitment began in parallel for a high-dose late-infantile GM1 cohort and a low-dose early-infantile GM1 cohort.
- Cohort 1 included two patients, with data available through eight months for patient 1 and two months for patient 2.
- No serious adverse events were reported. Reported adverse events were mild to moderate; moderate events resolved without intervention and were considered unrelated to treatment.
- No complications related to the intracisterna magna injection were observed, and nerve conduction studies showed no evidence of dorsal root ganglion toxicity.
- CSF beta-galactosidase activity increased 1.5-fold over baseline at 30 days for patient 1 and 4.8-fold for patient 2. Patient 1’s increase remained at six months.
- Serum beta-galactosidase activity was slightly above baseline at 30 days and 1.7-fold over baseline at three months for patient 1, with the increase maintained at six months. Patient 2 showed a 1.2-fold increase at 30 days.
- CSF GM1 ganglioside levels increased approximately 85% for patient 1 at 30 days and remained stable through six months. Patient 2’s levels decreased approximately 46% at 30 days.
- On December 8, 2021, the Company exercised two additional options under its University of Pennsylvania collaboration and licensing agreement for Huntington’s disease and Canavan disease programs.
Outlook, Risks, and Unusual Items
- The Company expected to dose the first patients in global Phase 1/2 trials for frontotemporal dementia with granulin mutations and Krabbe disease in early 2022.
- The Company expected to provide updated data-readout timing guidance for those studies after the first patients were dosed.
- The reported Imagine-1 results are interim results from only two patients and may not predict results in larger cohorts or later-stage studies.
- The filing provides safety and biomarker data but does not report clinical efficacy outcomes, regulatory approvals, or commercialization timing.
- Items 7.01 and the related exhibits were furnished rather than filed for purposes of Section 18 of the Exchange Act and generally were not incorporated by reference into other filings unless expressly stated.
Investor Verification Items
- Verify subsequent safety, biomarker, and clinical efficacy results from the additional Imagine-1 cohorts.
- Confirm patient enrollment, dosing, and data-readout timing for the frontotemporal dementia and Krabbe disease trials.
- Review the Company’s subsequent periodic reports for cash runway, operating expenses, financing activity, collaboration obligations, and liquidity.
- Assess whether later regulatory or clinical developments changed the outlook for PBGM01 and the broader pipeline.